Latest Pyrazines Stories
-- Studies focused on patients where there is a high unmet need today or anticipated in the near future -- BOSTON, Nov.
- Note: This release corresponds to ASH abstracts 22, 31, 78, 84, 176, 327, 505, 2096, 2312, 3448, 3474, 4454, 4469, 4680 RARITAN, N.J., Nov.
MarketOptimizer.org adds “PharmaPoint: Hepatitis C Virus – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update” to its store.
Results show adding LBH589 to bortezomib and dexamethasone significantly improved PFS by 37%, meeting Phase III study primary endpoint1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis
The new interferon-free, all-oral, three direct-acting-antiviral (3D) treatment regimen in development by AbbVie has achieved very high rates of virological response in patients chronically infected with hepatitis C virus (HCV) genotype 1 (GT1); according to the results of three studies presented today at the International Liver CongressTM 2014.
Robust Clinical Data on Filanesib Presented at ASH Supporting Announced Registration Program BOULDER, Colo., Feb. 4, 2014 /PRNewswire/ -- Array BioPharma Inc.
Five Distinguished Researchers Receive First-Time Grant WHITE PLAINS, N.Y., Jan.
AllMed webinar provides in-depth review of the latest in the standard of care for the treatment of hepatitis C virus (HCV) infection. Portland, OR (PRWEB) November
- A transitional zone between two communities containing the characteristic species of each.